Reply to the Letter to the Editor ‘Comments on the study of correlation between progression-free and overall survival in patients with Hodgkin lymphoma’ by Zeng et al.

We would like to thank Drs Zeng and colleagues for their interest1 in our comprehensive analysis of individual data from >10 000 patients showing a strong correlation between progression-free survival (PFS) and overall survival (OS) after 26 different types of first-line treatment within nine randomized, international academic trials.2

[News] Call to prioritise access to essential cancer medicines in Latin America and the Caribbean

On Feb 3, 2025, the Pan American Health Organization (PAHO) issued a statement calling on countries in Latin America and the Caribbean to prioritise access to essential cancer medicines. The statement noted that there are more than 4 million new cases of cancer every year in the Americas and over 1·4 million deaths. Patients do… Continue reading [News] Call to prioritise access to essential cancer medicines in Latin America and the Caribbean

[Articles] Overall survival and quality of life with [177Lu]Lu-PSMA-617 plus enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer (ENZA-p): secondary outcomes from a multicentre, open-label, randomised, phase 2 trial

The addition of [177Lu] Lu-PSMA-617 to enzalutamide was associated with improved survival and some aspects of HRQOL in patients with high-risk metastatic castration-resistant prostate cancer. Our findings warrant phase 3 evaluation of adaptive-dosed [177Lu] Lu-PSMA-617 in combination with androgen receptor pathway inhibitors in people with metastatic prostate cancer.

Blinatumomab Boosts Chemotherapy as Initial Treatment for Some Kids with ALL

Following positive results from a clinical trial, the immunotherapy drug blinatumomab (Blincyto) is expected to become part of the standard initial treatment for many kids with B-cell acute lymphoblastic leukemia, the most common form of childhood cancer.

Relationships between patient‐reported and clinician‐rated toxicities and daily functioning in older adults with advanced cancer undergoing systemic therapy

Abstract Background Older adults with advanced cancer are at higher risk of treatment-related toxicities, which can impair function. Relationships between clinician-rated and patient-reported toxicities with functional decline remain unclear. Methods This secondary analysis of the GAP70+ trial aimed to evaluate the associations between clinician-rated (Clinician-rated common Terminology Criteria for Adverse Events [CTCAE]) and patient-reported toxicities… Continue reading Relationships between patient‐reported and clinician‐rated toxicities and daily functioning in older adults with advanced cancer undergoing systemic therapy

Published
Categorized as Oncology

Maintenance therapy with the FMS‐like tyrosine kinase 3 inhibitor gilteritinib in patients with FMS‐like tyrosine kinase 3–internal tandem duplication acute myeloid leukemia: A phase 2 study

Abstract Background The GOSSAMER phase 2 study assessed the FMS-like tyrosine kinase 3 (FLT3) inhibitor gilteritinib as maintenance therapy in patients with FLT3–internal tandem duplication (FLT3-ITD) acute myeloid leukemia (AML) in first complete remission without previous hematopoietic stem cell transplantation (HSCT). Methods Patients had to be within 2 months of their last consolidation cycle and… Continue reading Maintenance therapy with the FMS‐like tyrosine kinase 3 inhibitor gilteritinib in patients with FMS‐like tyrosine kinase 3–internal tandem duplication acute myeloid leukemia: A phase 2 study